Mikhail Blagosklonny is a scientist who has devoted his career to research on cancer and aging. The Roswell Park Cancer Institute professor of oncology has a strong educational background and a vast experience in oncology. He earned both medical degree in internal medicine and Ph.D. in cardiology and experimental medicine from St. Petersburg’s First Pavlov State Medical University.
Before joining Roswell Park Cancer Institute in 2009, Prof. Mikhail had worked as a senior scientist in charge of research strategies at Ordway Research Institute. He had also been an associate professor at the New York Medical College in 2002. His extensive knowledge, experience, and research led to his appointment as the professor of Oncology at Roswell Park Cancer Institute.
Blagosklonny’s research work focuses majorly on cancer therapies that can prevent the damage of healthy human cells. He also studies aging in humans with the aim of producing anti-aging drugs. Additionally, Mikhail Blagosklonny researches and writes on areas like signal transduction, cell cycle, ontogenesis, apoptosis, and mitosis.
Based on his studies and research work, he has become a zealous advocate of the cancer drug, rapamycin because he believes it is possible to cure cancer. Rapamycin is traditionally used to minimize the multiplication of cancer cells. Mikhail Blagosklonny believes it has the potential of boosting the immunity of cancer patients as well. He has even written a hypothesis proposing the use of rapamycin in TOR signaling to counteract aging and disease by targeting specific cell and tissue operation. Visit classroomvoices.org to read more about Mikhail.
Apart from scientific research, Mikhail works as the editor in chief of the medical journals, Oncotarget and Cell cycle and as the associate editor of Cancer and Biology Therapy. Mikhail serves on the editorial council of members of Differentiation Journal and Cell Death. Other science journals which employ his editorial expertise include the American Journal of Pathology, PLOS ONE and the International Journal of Cancer.
As a result of his tremendous contributions, Mikhail Blagosklonny ranks among the world’s greatest oncology researchers. He has over 300 research articles, reviews, and book chapters that bear his name. The author of aging hyperfunction theory also writes publications about chemotherapeutic engineering and cell cyclotherapy. Mikhail has believed in keeping the public informed on the trends in cancer and aging fields.
Mikhail thinks that it is possible for the society to be disease-free, without the effects of cancer and aging. Therefore, he has dedicated his time and effort to carry out more research on oncology. Many ridiculed the work of this great scientist at the beginning, but numerous separate studies have proved the truth of Mikhail’s hypothesis concerning TOR signaling and rapamycin as today’s ant-aging drug. He believes that the next topic in longevity research will be about the post-aging syndrome.